Ireland· IE-PA-EU/1/22/1649/004
Lunsumio 45 mg solution for injection
A mosunetuzumab product containing mosunetuzumab, registered in Ireland by Roche Registration GmbH. The same ATC class is registered in 12 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Mosunetuzumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FX25 (mosunetuzumab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Mosunetuzumab · ATC L01FX25
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Mosunetuzumab
- Manufacturer
- Roche Registration GmbH
- Country
- Ireland (IE)
- ATC code
- L01FX25
- ATC class
- Mosunetuzumab
- Defined daily dose
- 1.8 mg, P
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/22/1649/004
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mosunetuzumab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsLunsumio 45 mg oplossing voor injectieRoche Registration GmbH
- United StatesLunsumioGenentech, Inc.
- FinlandLunsumioOrifarm Oy
- CzechiaLUNSUMIORoche Registration GmbH, Grenzach-Wyhlen
- SpainLUNSUMIO 1 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- BelgiumLunsumio 1 mgRoche Registration
- SwitzerlandLunsumio 1 mg/1 ml, Konzentrat zur Herstellung einer InfusionslösungRoche Pharma (Schweiz) AG
- PolandLunsumioRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lunsumio
- Liechtenstein · Lunsumio
- Norway · Lunsumio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4fcd141d-3507-4638-9b7f-abaae1fbce9e GET /v1/drugs/4fcd141d-3507-4638-9b7f-abaae1fbce9e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"routes": [
"Subcutaneous use"
],
"source": "hpra",
"atc_all": [
"L01FX25"
],
"strength": null,
"pa_number": "EU/1/22/1649/004",
"substances": [
"Mosunetuzumab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "17/11/2025",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about mosunetuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.